Veterinary Advisor

• Mar 2023 - Present

Responsible for launching Catalysis pet products in Abu Dhabi and Al Ain. Responsible for launching Catalysis pet products in Abu Dhabi and Al Ain.

Medical Representative

• Jan 2023 - Mar 2023

• Responsible for the launch of Modern Saw Palmeto for BPH patients with staff Urologists in Downtown • Responsible for the launch of Cranberry for UTI patients with staff Urologists and Gynacologists • Responsible for the launch of Modern D Kids ans Santabiota ( probiotic) for kids with staff Pediatricians • Responsible for the launch of Modern Saw Palmeto for BPH patients with staff Urologists in Downtown • Responsible for the launch of Cranberry for UTI patients with staff Urologists and Gynacologists • Responsible for the launch of Modern D Kids ans Santabiota ( probiotic) for kids with staff Pediatricians

Sales Excutive

• Nov 2021 - Oct 2022

• Promoting CME credits to HCPs through our own online platform • Expanded customer database in 2 week time to 50 subscribers. • Promoting medical courses such as BLS, Infection Control, First aid. • Promoting CME credits to HCPs through our own online platform • Expanded customer database in 2 week time to 50 subscribers. • Promoting medical courses such as BLS, Infection Control, First aid.

Medical Representative

• Dec 2018 - Oct 2021

• Expanded customer database through the drug Erastapex (Olmesartan) during 2019-2020 with ytd 120% making us the market leaders with a market share of 40% and introducing it to Egyptian MOH, Health Insurance Hospital • Leading the launch of the drug Diacurimap (Empagliflozin) in Maadi & Helwan territories and was able to achieve ytd 92% and grew market share by 20%. • Managing multiple territories covering the specialties: Cardiovascular, Internal medicine, Diabetology, GIT, Nephrology… Show more • Expanded customer database through the drug Erastapex (Olmesartan) during 2019-2020 with ytd 120% making us the market leaders with a market share of 40% and introducing it to Egyptian MOH, Health Insurance Hospital • Leading the launch of the drug Diacurimap (Empagliflozin) in Maadi & Helwan territories and was able to achieve ytd 92% and grew market share by 20%. • Managing multiple territories covering the specialties: Cardiovascular, Internal medicine, Diabetology, GIT, Nephrology, Pediatric, Orthopedic, and Dermatology • Worked on different therapeutic areas and different drugs:  Ezapril ( Enalapril ACE I)  Carvid ( Carvidelol B blocker)  Eraloner ( MRA)  Itrapex ( Itraconazole)  Nizapex ( ketoconazole)  Stoka ( Clopidogrel)  Elbavit ( Multivitamin for pediatrics)  Examide ( Torsemide diuretic)  Mavilor ( Nebivelol vasodilating B blocker)  Allerban ( Ketotifen )  Apexidone ( Antipsychotic)  Erastapex ( ARB)  Diacurimap ( Empagliflozin) Show less • Expanded customer database through the drug Erastapex (Olmesartan) during 2019-2020 with ytd 120% making us the market leaders with a market share of 40% and introducing it to Egyptian MOH, Health Insurance Hospital • Leading the launch of the drug Diacurimap (Empagliflozin) in Maadi & Helwan territories and was able to achieve ytd 92% and grew market share by 20%. • Managing multiple territories covering the specialties: Cardiovascular, Internal medicine, Diabetology, GIT, Nephrology… Show more • Expanded customer database through the drug Erastapex (Olmesartan) during 2019-2020 with ytd 120% making us the market leaders with a market share of 40% and introducing it to Egyptian MOH, Health Insurance Hospital • Leading the launch of the drug Diacurimap (Empagliflozin) in Maadi & Helwan territories and was able to achieve ytd 92% and grew market share by 20%. • Managing multiple territories covering the specialties: Cardiovascular, Internal medicine, Diabetology, GIT, Nephrology, Pediatric, Orthopedic, and Dermatology • Worked on different therapeutic areas and different drugs:  Ezapril ( Enalapril ACE I)  Carvid ( Carvidelol B blocker)  Eraloner ( MRA)  Itrapex ( Itraconazole)  Nizapex ( ketoconazole)  Stoka ( Clopidogrel)  Elbavit ( Multivitamin for pediatrics)  Examide ( Torsemide diuretic)  Mavilor ( Nebivelol vasodilating B blocker)  Allerban ( Ketotifen )  Apexidone ( Antipsychotic)  Erastapex ( ARB)  Diacurimap ( Empagliflozin) Show less

Product Specialist

• Sep 2017 - Dec 2018

• Exclude the brand from different tender organizations such as AOH, Iron and steel company. • Increasing market share 30% of Torseretic ( diuretic). • Launching Downsterolin ( combination therpy for dylipidemic patient). • Exclude the brand from different tender organizations such as AOH, Iron and steel company. • Increasing market share 30% of Torseretic ( diuretic). • Launching Downsterolin ( combination therpy for dylipidemic patient).

Medical Representative

• May 2015 - Sep 2017

• Responsible on Suez Canal for promoting orthopedic portfolio :  Kemerica ( pregabalin)  Rosuvast ( rosuvastatin)  Kansartan ( ARB)  Rheuxicam ( NSAID)  Neurimax ( vit B) • Responsible on Helwan – Cairo on launching :  Maxidinir ( Cefdinir)  Hormoston ( dedrgestrone hormonal therapy)  Allevo ( levocetirizine)  Notussil ( Anti-cough)  Ornidaz ( ornidazole) • Responsible on Suez Canal for promoting orthopedic portfolio :  Kemerica ( pregabalin)  Rosuvast ( rosuvastatin)  Kansartan ( ARB)  Rheuxicam ( NSAID)  Neurimax ( vit B) • Responsible on Helwan – Cairo on launching :  Maxidinir ( Cefdinir)  Hormoston ( dedrgestrone hormonal therapy)  Allevo ( levocetirizine)  Notussil ( Anti-cough)  Ornidaz ( ornidazole)

First Lieutenant

• Oct 2012 - Apr 2015